Biotech companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Biogen has the lowest figure of the 19 biotech companies ranked by P/S ratio, at 3.8, followed by Qiagen (4.9) and Neurocrine Biosciences (5.8). Figures as of 18 Nov 2026, 18:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 19
- Lowest
- Biogen3.8
- Median
- 14.3
- Combined market value
- THB 28.54T
- Countries
- 5
- Not ranked
- 5no P/S ratio on file
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | BiogenBIIB · Health Care | 3.8 | THB 1.27T | THB 8,559.13 | 0.53% up | 49% up | ||
| 2 | QiagenQGEN · Health Care | 4.9 | THB 348.4B | THB 1,687.32 | 0.10% down | 12% up | ||
| 3 | Neurocrine BiosciencesNBIX · Health Care | 5.8 | THB 563.5B | THB 5,566.78 | 1.18% down | 20% up | ||
| 4 | BioNTechBNTX · Health Care | 6.5 | THB 706.1B | THB 2,848.07 | 1.14% down | 16% down | ||
| 5 | AmgenAMGN · Health Care | 6.6 | THB 8.2T | THB 15,154.94 | 2.52% down | 34% up | ||
| 6 | Gilead SciencesGILD · Health Care | 7.1 | THB 7.12T | THB 5,737.89 | 0.73% down | 33% up | ||
| 7 | ExelixisEXEL · Health Care | 7.3 | THB 571.8B | THB 2,343.21 | 0.76% up | 63% up | ||
| 8 | Halozyme TherapeuticsHALO · Health Care | 7.9 | THB 372.9B | THB 3,271.09 | 0.40% up | 37% up | ||
| 9 | Bio-TechneTECH · Health Care | 9.4 | THB 388.3B | THB 2,471.73 | 0.24% up | 26% up | ||
| 10 | argenxARGX · Health Care | 14.3 | THB 2.02T | THB 32,148.44 | 0.06% down | 4% up | ||
| 11 | RepligenRGEN · Health Care | 15.0 | THB 376.3B | THB 5,886.93 | 6.92% up | 5% up | ||
| 12 | Adaptive BiotechnologiesADPT · Health Care | 16.8 | THB 158.2B | THB 977.59 | 1.07% up | 88% up | ||
| 13 | Twist BioscienceTWST · Health Care | 21.4 | THB 274.1B | THB 4,020.02 | 5.72% up | 340% up | ||
| 14 | Krystal BiotechKRYS · Health Care | 24.0 | THB 317.2B | THB 10,705.11 | 5.62% up | 46% up | ||
| 15 | ModernaMRNA · Health Care | 41.6 | THB 2.74T | THB 6,781.00 | 3.42% down | 755% up | ||
| 16 | ImmunityBioIBRX · Health Care | 63.1 | THB 242.5B | THB 227.97 | 7.27% up | 193% up | ||
| 17 | Kymera TherapeuticsKYMR · Health Care | 266 | THB 353.9B | THB 4,145.30 | 0.48% up | 87% up | ||
| 18 | CRISPR TherapeuticsCRSP · Health Care | 1146 | THB 136.5B | THB 1,407.40 | 3.25% up | 21% down | ||
| 19 | CG OncologyCGON · Health Care | 1774 | THB 243.3B | THB 2,723.81 | 1.63% up | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 33.9500 THB). 5 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which biotech companies have the lowest P/S ratio?
Biogen (3.8), Qiagen (4.9) and Neurocrine Biosciences (5.8) have the lowest P/S ratio of the 19 biotech companies ranked here as of 18 Nov 2026, 18:41 UTC.
How many biotech companies are in this ranking?
19 are ranked by P/S ratio. 5 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these biotech companies worth together?
The 19 biotech companies ranked by P/S ratio have a combined market value of THB 28.54T as of 18 Nov 2026, 18:41 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech companies by P/S ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.